Old Road Campus Research Building, Roosevelt Drive Oxford, OX3 7DQ
Sponsor: University of Oxford
Clinical Trials.gov Number: NCT02145416
A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.
Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.
Submitted by adm1n on
Submitted by adm1n on
Submitted by adm1n on
ATR inhibitor and chemoradiotherapy in oesophageal cancer.
This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).
The study is in setup with a planned opening date of May 2016. A CRUK New Agents Committee grant has been awarded for this study (CRUKD/15/011). Site selection will include Oxford, Leeds & Glasgow.
We are interested in the mechanisms underlying the development of metastasis, the spread of cancer from one part of the body to another.
Our goals are to identify the role of the inflammatory and metabolic microenvironment in brain metastasis, and to develop imaging biomarkers for tumour detection and monitoring.
The aim of our research is to design and develop innovative cancer killing viruses and oncolytic vaccines.
Our research links basic science with clinical applications and focuses on understanding the mechanisms behind tumour resistance to radiation.
Our research aims to understand the cell and molecular biology behind frequent tumour mutations and how they influence cancer onset and/or therapy.
